← 返回

葛根素靶向 MIC19 抑制肿瘤浸润性 Tregs 的线粒体代谢并增强抗肿瘤免疫

英文原题:Puerarin Targets MIC19 to Suppress Mitochondrial Metabolism of Tumor-Infiltrating Tregs and Enhance Anti-tumor Immunity.

查看英文原题

Puerarin Targets MIC19 to Suppress Mitochondrial Metabolism of Tumor-Infiltrating Tregs and Enhance Anti-tumor Immunity.

PubMed 2025/11/18(内容时间) Adv Sci (Weinh) Q1 · IF 14.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

调节性T细胞(Tregs)是肝细胞癌中免疫抑制的关键介质,但选择性破坏其功能的策略仍不成熟。本研究将葛根素——一种天然异黄酮——鉴定为选择性免疫代谢调节剂。它损害肿瘤浸润性Tregs(Ti-Tregs)的线粒体代谢,而不影响常规T细胞。机制上,葛根素直接结合MIC19——线粒体接触位点和嵴组织系统的核心亚基——导致其降解并破坏MIC19-MIC60复合物。这种破坏引起嵴结构紊乱,降低氧化磷酸化,并削弱Ti-Tregs的免疫抑制功能。在体内,葛根素减少Ti-Treg浸润,从而增强抗肿瘤免疫而不引起全身毒性。此外,MIC19敲低和定点突变研究验证了关键MIC19残基(His180、Gln187和Tyr211)在葛根素活性中的作用。这些结果揭示了葛根素抑制Ti-Tregs线粒体代谢的机制,并强调了天然化合物在癌症免疫治疗中代谢靶向的治疗潜力。

展开英文摘要原文

Regulatory T cells (Tregs) are pivotal mediators of immunosuppression in hepatocellular carcinoma, but strategies for selectively disrupting their function remain underdeveloped.

Here, puerarin, a natural isoflavone is identifed as a selective immunometabolic modulator. It impairs mitochondrial metabolism in tumor-infiltrating Tregs (Ti-Tregs) without affecting conventional T cells.

Mechanistically, puerarin directly binds to MIC19-a core subunit of the mitochondrial contact site and cristae organizing system-leading to its degradation and disruption of the MIC19-MIC60 complex. This disruption causes cristae disorganization, reduces oxidative phosphorylation, and weakens the immunosuppressive function of Ti-Tregs. In vivo, puerarin decreases Ti-Treg infiltration, thereby enhancing antitumor immunity without causing systemic toxicity.

Furthermore, MIC19 knockdown and site-directed mutagenesis studies validate the role of critical MIC19 residues (His180, Gln187, and Tyr211) in puerarin's activity. These results reveal a mechanism by which puerarin suppresses mitochondrial metabolism of Ti-Tregs and emphasize the therapeutic potential of natural compounds in metabolic targeting for cancer immunotherapy.

论文信息

作者
Li Y、Song Z、Ding J、Zhou Y、Huang T、Qian Q、Yu M、Chen W
单位
Collaborative Innovation Center for Cancer Personalized Medicine and Hepatobiliary Center, The First Hospital Affiliated with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China.China
期刊
Advanced science (Weinheim, Baden-Wurttemberg, Germany)2026 Jan
原文标识
PubMed 41250935 · DOI 10.1002/advs.202512793